Skip to main content
Top
Published in: Oncology and Therapy 2/2024

Open Access 04-05-2024 | Radiotherapy | Editorial

Some Considerations on the Treatment of Laryngeal Verrucous Squamous Cell Carcinoma

Authors: Primoz Strojan, Alfio Ferlito

Published in: Oncology and Therapy | Issue 2/2024

Login to get access

Excerpt

Laryngeal verrucous squamous cell carcinoma (LVSCC) is a distinct pathologic and clinical variant of well-differentiated squamous cell carcinoma and accounts for 1–3.4% of malignancies of the larynx [1, 2]. The larynx is the most common site within the respiratory tract and the second most common site in the body after the oral cavity [3]. LVSCC usually develops in white men (90%) in their late 60s who have a history of heavy smoking, and most commonly (80%) affects the glottic portion of the larynx [1]. Histologic confirmation of LVSCC is often difficult and requires multiple biopsies, which can significantly delay diagnosis [2]. At diagnosis, 80% of tumors are classified as T1 or T2 [1]. Cervical and distant metastases have not been reported in true cases of verrucous squamous cell carcinoma. Enlarged lymph nodes are uncommon in these patients, and only reactive changes are expected on histologic examination, so elective treatment in the neck is not warranted [2]. However, cases of hybrid verrucous carcinoma in which foci of squamous cell carcinoma are found on histopathologic examination must be treated as aggressively as conventional squamous cell carcinoma. This includes elective treatments such as neck dissection or postoperative chemo-radiotherapy (RT) once the full pathologic features of the primary tumor are known. In addition, patients with verrucous carcinoma tend to develop a second malignant tumor either in the upper airway or elsewhere due to their close association with smoking, necessitating strict follow-up after treatment of the first tumor [1, 2, 4]. …
Literature
10.
go back to reference Ferlito A, Rinaldo A, Mannarà GM. Is primary radiotherapy an appropriate option for the treatment of verrucous carcinoma of the head and neck? J Laryngol Otol. 1998;112:132–9.CrossRefPubMed Ferlito A, Rinaldo A, Mannarà GM. Is primary radiotherapy an appropriate option for the treatment of verrucous carcinoma of the head and neck? J Laryngol Otol. 1998;112:132–9.CrossRefPubMed
11.
go back to reference Strojan P, Šoba E, Budihna M, Auersperg M. Radio (chemo) therapy and anaplastic transformation in verrucous carcinoma of the head and neck (Letter to the Editor). J Surg Oncol. 2006;94:640–1.CrossRef Strojan P, Šoba E, Budihna M, Auersperg M. Radio (chemo) therapy and anaplastic transformation in verrucous carcinoma of the head and neck (Letter to the Editor). J Surg Oncol. 2006;94:640–1.CrossRef
12.
go back to reference Medina JE, Dichtel W, Luna MA. Verrucous-squamous carcinomas of the oral cavity: a clinicopathologic study of 104 cases. Arch Otolaryngol. 1984;110:437–40.CrossRefPubMed Medina JE, Dichtel W, Luna MA. Verrucous-squamous carcinomas of the oral cavity: a clinicopathologic study of 104 cases. Arch Otolaryngol. 1984;110:437–40.CrossRefPubMed
Metadata
Title
Some Considerations on the Treatment of Laryngeal Verrucous Squamous Cell Carcinoma
Authors
Primoz Strojan
Alfio Ferlito
Publication date
04-05-2024
Publisher
Springer Healthcare
Keyword
Radiotherapy
Published in
Oncology and Therapy / Issue 2/2024
Print ISSN: 2366-1070
Electronic ISSN: 2366-1089
DOI
https://doi.org/10.1007/s40487-024-00277-4

Other articles of this Issue 2/2024

Oncology and Therapy 2/2024 Go to the issue
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare